Medicare Advantage outperformed traditional Medicare on clinical quality measures before and during the COVID-19 pandemic; mid-pandemic, however, traditional Medicare narrowed the gap on some in-person screenings.

Patients who would be high-risk based on conventional assessments tended to have higher median QRISK3 scores in the study. | Image credit: Eleni - stock.adobe.com

QRISK3 Tool Predicts Thrombotic Events in ET, PV

By Jared Kaltwasser

August 8th 2025

The QRISK3 assessment is designed for the general population, but it appears to also have utility in patients with essential thrombosis and polycythemia vera.

Zongertinib Granted Accelerated Approval in Nonsquamous NSCLC for HER2 TKD-Activating Mutations

By Mary Caffrey
Brooke McCormick

August 8th 2025

Zongertinib gains FDA approval for treating HER2-mutated non–small cell lung cancer (NSCLC), offering hope with fewer side effects and promising response rates in patients.

Semaglutide injectors and stethoscope | Image credit: Nati – stock.adobe.com

Semaglutide Linked to Cardiovascular Gains, but Also Higher Health Spending

By Hayden E. Klein

August 8th 2025

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and cholesterol, but also a $80 monthly rise in health care spending outside of drug costs.

BRUIN CLL-314 was the first-ever head-to-head trial of pirtobrutinib versus ibrutinib that included treatment-naive patients. | Image credit: fotogurmespb - stock.adobe.com

New Pirtobrutinib Data Compare Favorably With Ibrutinib in CLL/SLL

By Jared Kaltwasser

August 7th 2025

Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

...

112 113 114 115 116

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions